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Abstract
Background: MEFV mutations and decreased expression level of the gene are related to FMF pathology. DNA
methylation at CpG islands is a well-known mechanism for transcriptional silencing. MEFV has a CpG island,
spanning a part of the first intron and the whole of the second exon of the gene covering 998 bp region. Here,
we tested the hypothesis that the MEFV transcript level in FMF patients correlates with its methylation level, and
methylation, by allowing transcription silencing, has a role in FMF ethiopathogenesis.
Methods: The study group was composed of pediatric FMF patients (N = 51) and age-gender matched healthy
controls (N = 21). The relative expression level of MEFV was assessed via quantitative real-time PCR (qRT-PCR) and
bisulfite sequencing (BS) was performed to analyse the methylation level quantitatively.
Results: MEFV expression in FMF patients were decreased compared to healthy controls (P = 0.031). Methylation level
of exon 2 of MEFV was found to be slightly higher in FMF patients compared to healthy controls (76% versus 74%) (P =
0.049). The expression level of the MEFV was negatively correlated with the methylation level of the CpG island in both
FMF and healthy controls groups (cor = -0.29, P = 0.041) but more so in the FMF only group (cor = -0.36, P =0 . 0 3 5 ) .
Conclusions: In this study, the relation between reduced MEFV expression level and FMF was confirmed. Observed
slight increase in methylation in FMF patients, and correlation of methylation with expression might be indicative
of its role in FMF, however a larger dataset is needed to confirm our preliminary findings.
Background
Familial Mediterranean Fever (FMF) is an autoinflamma-
tory disease that commonly affects Mediterranean people;
mostly Turks, Jews, Armenians and Arabs. Typical symp-
toms of the disease are recurrent attacks of fever, and the
inflammation of serosal membranes with abdominal pain
[1]. MEFV is the first identified inflammatory gene, which
is responsible for FMF [2,3]. Approximately 70 variations
on MEFV gene are related to FMF. The most common
five mutations, M694V, M694I, M680I and V726A in
exon10 and E148Q in exon 2, are attributed approximately
%80 of disease associated alleles in FMF patients coming
from Mediterranean ancestry with clear clinical criteria
[4-6].
MEFV gene encodes Pyrin/Marenostrin which is mainly
expressed in neutrophils, eosinophils, cytokine activated
monocytes, dendritic cells and synovial fibroblasts. Pyrin/
Marenostrin has a role in inflammation by activation of
caspase-1, which is responsible for the maturation of IL-1b
and by activation of NF-B. Recent studies show that
Pyrin/Marenostrin is an inflammatory regulator, which
acts as pro-inflammatory and anti-inflammatory [7,8]. Sev-
eral different transcript isoforms were shown, MEFV-d2,
MEFV-8ext, MEFV-4a, MEFV-2a, del34, del234, del2345,
del7, del78, in previous studies. Full-length Pyrin/Marenos-
trin, 781 amino acids, is located at cytoplasm and related
with microtubule and actin filaments by B30.2 domain of
Pyrin/Marenostrin. Alternatively spliced form of Pyrin/
Marenostrin, translated from the exon 2 lacking MEFV-d2
transcript, which is 570 amino acids long, is located mainly
at the nucleus [9-11]. MEFV gene is regulated by non-
sense-mediated decay and different isoforms of MEFV
transcripts have different cellular localization and functions
in inflammation [12].
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FMF patients compared to healthy controls and
decreased mRNA expression level was correlated with
mutation number [13]. Furthermore, the MEFV expres-
sion level was found to be more decreased in FMF
patients during attacks. This indicates that the lower
mRNA levels of MEFV are related to inflammation [14].
Despite two previous studies, a more recent study found
that the MEFV expression level was not significantly dif-
ferent in groups, even slightly higher in FMF patients
compared to healthy controls. Further Pyrin/Marenostrin
levels in granulocytes were found significantly higher in
FMF patients [15].
DNA methylation, the most common epigenetic mechan-
ism, occurs at the cytosine bases in CpG islands present in
the gene promoter [16]. In addition to that, methylation of
CpG islands at first and second exons cause also transcrip-
tional silencing by preventing the RNA polymerase II tran-
scription elongation [17].
The MEFV gene contains a CpG island spanning the
complete second exon and a part of first intron. Since,
methylation is an important mechanism of gene regula-
tion and the lower expression of MEFV is associated with
FMF and inflammation, methylation at the second exon
of MEFV might have a role in FMF pathology. In this
study, we aimed to compare MEFV expression and
methylation levels between FMF patients and healthy
controls.
Methods
Sample Information
Peripheral leukocytes were obtained from 51 FMF patients
(26 female, 25 male) and 21 healthy children (8 female, 13
male) who came to the Pediatric Outpatient Clinic of Cer-
rahpasa Medical Faculty, Istanbul University. None of the
patients had attacks of serositis and fever at the time of
sample collection. All FMF patients were on Colchicine.
The mean age of FMF patients were 10.3 ± 4.02 and
healthy controls were 8 ± 3.71. The control group was
chosen among children who came to the clinic either for a
general check up or were diagnosed with a non - inflam-
matory disease. The Ethics Review Committee of Istanbul
University Cerrahpasa Medical Faculty approved the
study. The parents of children were informed and consent
forms were fulfilled.
Mutation Analysis
Genomic DNA was isolated from venous blood samples
using DNA Isolation Kit for Mammalian Blood (Roche
Diagnostics, Mannheim, Germany). To analyse the most
common 5 mutations in Turkish population; E148Q,
M680I, M694I, M694V and V726A, PCR-RFLP method
was used [18].
Gene Expression Analysis
Total RNA was isolated from whole leukocytes using High
Pure RNA Isolation Kit (Roche Diagnostics, Mannheim,
Germany). For prevention of RNA degradation, cDNA
synthesis was done immediate l yf o l l o w e db yt o t a lR N A
isolation by using Transcriptor First Strand cDNA Synth-
esis Kit (Roche Diagnostics, Mannheim, Germany). In 51
FMF patients and 11 healthy controls, probe based quanti-
tative real - time PCR was done by LightCycler
® TaqMan
Master Kit (Roche Diagnostics, Mannheim, Germany) and
performed at LightCycler
® 2.0 system to measure MEFV
mRNA level. Primer and probes were designed at Univer-
sal ProbeLibrary website of Roche http://www.roche-
applied-science.com/sis/rtpcr/upl/index.jsp?id=UP030000.
The primer set spanning to the junction of exon 4-5 and
UPL Probe8 were used for quantitative real time PCR. The
primer sequences were as follows; Forward: 5’- AGGAG-
CAGCGATCCTATGG-3’ and reverse: 5’-CAGCGCTT-
CAGTTTGTTTCA-3’. This set detects transcripts with or
without exon 2 MEFV.
T h eB 2 Mg e n ew a su s e da sar e f e r e n c eg e n e( B 2 M
Gene Assay-Roche Diagnostics, Mannheim, Germany).
The relative expression level was calculated using ΔCT
method (ΔCT=C T of b2M - CT of MEV, 2
-ΔC
T value
indicates the fold change between target gene and refer-
ence gene) [19].
Methylation Analysis
Bisulfite treatment was done to obtain two different DNA
sequences for methylated and unmethylated forms accord-
ing to the supplier’s protocol of the CpGenome DNA
Modification Kit (Millipore, Billerica, MA, USA). Bisulfite
sequencing (BS) was performed to measure the methyla-
tion status of second exon of MEFV gene. To amplify 41
CG dinucleotides at second exon of the gene, BS primers
which are common for both bisulfite treated methylated
and bisulfite treated unmethylated sequences were
designed using MethPrimer software [20]. The primer
sequences were as follows; Forward: 5’- GTTTTTTGGGG
GAGAATAAG -3’ and Reverse: 5’ - TTTCCAAAACCTT
CCTTCAAAT -3’. After PCR with BS primers, sequencing
was performed (ABI PRISM
® 3100 Analyzer, Applied
Biosystems, Foster City, CA). To analyse sequencing,
alignment was done using QUantification tool form
Methylation Analysis (QUMA) [21] and cytosine peak
height (x) and thymidine peak height (y) were measured
for each CpG using ChromasPRO. Relative cytosine peak
height was calculated by x/x+y formulas.
Statistical Analysis
Mutation results between FMF patients and healthy
controls were analysed by Chi square test and expres-
sion and methylation variations between FMF patients
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test. Correlation between expression and methylation
levels was done by the Spearman correlation analysis.
All statistical analyses were done using GraphPad Prism
5 software.
Results
Genotyping Analysis
MEFV allele frequencies were compared between FMF
patients and healthy controls. The observed allele fre-
quencies are given in table 1. Significantly, differences
were found between the mutations frequencies of FMF
patients and healthy controls (Mantel Haenszel chi
square = 9.912 (P = 0.0016), Odds Ratio: 2.7689 95% CI:
1.7302< O.R. <14.7894).
MEFV Expression
Relative expression levels were calculated for FMF
patients (N = 51) and healthy controls (N = 11) by the
ΔCT method [19]. We observed that the MEFV expres-
sion level was significantly decreased in FMF patients
compared to healthy controls (about 2 fold, P =0 . 0 3 )
(Figure 1). We did not find significant differences
between FMF patients with mutations and FMF patients
without mutations (P = 0.70) (data not shown).
Methylation Level of The Second Exon of MEFV
The second exon of MEFV was found to comprise high
CG content (66%) and a 568 bp region containing 41
CpG dinucleotides corresponding to the whole of sec-
ond exon was selected for methylation analysis.
Methylation levels of the second exon of MEFV were
compared between 30 FMF patients and 21 healthy con-
trols by bisulfite sequencing (BS). The rest of the sample
could not be analysed because of methodological problems
that arose during BS. It is observed that the methylation
level is slightly but significantly higher in FMF patients
compared to healthy controls (P = 0.049) (Figure 2). Nega-
tive correlation between methylation and expression levels
was found in both groups (cor = -0.29, P = 0.041), but this
was higher in FMF samples-only group (cor = -0.36, P =
0.035) (Figure 3). Differences in methylation correlated
with expression levels between FMF patients and controls
can also be seen in Figure 4 where the higher MEFV
expression is correlated with lower methylation in FMF
group and the opposite is true for the control group.
Table 1 MEFV mutations frequency comparisons between
FMF patients and healthy controls
Variation FMF Allele Frequency
N = 102
Healthy Control Allele Frequency
N=2 2
M694V 45% -
M680I 5.8% 13.6%
V726A 1.9% 4.5%
M694I - -
E148Q 6.8% 4.5%
TOTAL 59.5% 22.6%
Figure 1 Expression Level of MEFV in FMF patients and
Healthy Controls. Expression levels were measured by quantitative
real time PCR analysis. RNA was obtained from peripheral leukocytes
as described in materials and methods. B2M gene was used as
reference gene and ΔCT method were used to relative
quantification. MEFV mRNA level was analyzed in 51 FMF patients
and 11 healthy controls. The bars represent standard deviations.
Two tail Student’s t-test was used to compare the MEFV expression
levels. The expression was significantly lower in FMF patients
compared to healthy controls (P = 0.031).
Figure 2 MEFV Methylation Levels in FMF Patients and Healthy
Controls. MEFV second exon methylation percentage in FMF
patients and healthy controls. Bisulfite sequencing was performed in
30 FMF patients and 21 healthy controls genomic DNAs that were
obtained from peripheral leukocytes. The bars represent standard
deviations. Statistical analysis was done using one tail Student’st -
test. Methylation level was observed slightly but significantly higher
in FMF patients compared to healthy controls (P = 0.049).
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Bioinformatic analysis showed that the MEFV gene has
high CG content (66%) at the second exon within a
CpG island of 568 bp. Here we aimed to investigate the
correlation between MEFV exon 2 methylation with its
expression, as methylation is a known mechanism for
decreasing gene expression and MEFV mRNA expres-
sion has been known to be reduced in FMF patients.
Initially we compared the expression levels of MEFV
in 51 FMF patients and 11 healthy controls. The expres-
sion level of the gene was significantly lower in FMF
patients (≈ two fold, P = 0.03). Our expression results
were consistent with two previous studies [13,14]. We
also compared MEFV mRNA levels between FMF
patients with mutations and FMF patients with no iden-
tified mutations. Contrary to previous studies, we did
not observe significant association between mutations
and expression levels of MEFV in FMF patients with or
without mutations; still, the expression level was slightly
higher in individuals without mutations. However due
to a small sample size, our study might be underpow-
ered to detect a significant difference.
Cytokines, such as TNF-a, IL-2 and IL-6 are known to
be associated with inflammatory diseases. The methylation
status of IL-6 promoter site was found to be lower in
rheumatoid arthritis patients compared to healthy controls
[22,23]. In addition to the effect of methylated promoters
on transcript levels, methylation of intragenic regions are
also known to cause reduction in expression by preventing
RNA Polymerase II elongation efficiency [17]. In this
Figure 3 Correlation Between Expression and Methylation Levels of MEFV. Negative correlation between expression and methylation levels
of MEFV was observed using Spearman pairwise correlation analysis. (A) Correlation between MEFV mRNA expression and methylation levels in
FMF patients (cor = -0.36, P= 0.035). (B) Negative correlation was also obtained between expression and methylation levels of MEFV when both
groups analysed (cor = -0.29, p = 0.041).
Figure 4 Expression and Methylation Levels of MEFV in FMF
Patients with Lowest Expression Level and Healthy Controls
with Highest Expression Level. MEFV expression and methylation
levels were compared between FMF patients with lowest expression
level (N = 4) and healthy controls with highest expression level (N =
4). The expression level is given as 2
-ΔC
TX 100. Error bars represent
standard deviation.
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levels of 41 CG dinucleotides at the MEFV second exon
were compared between 30 FMF patients and 21 healthy
controls using bisulfite sequence analysis. Methylation was
found slightly but significantly higher in FMF patients
than healthy controls (76% versus 74%) (one tail P =
0.049). Negative correlation between expression and
methylation was observed in all samples (cor = -0.29, P =
0.041), which was higher when only FMF patients were
analysed (cor = -0.36, P = 0.035). The power of the analy-
sis can be increased using a larger sample set.
Here we solely focused on methylation in exon 2 even if
the CpG island compasses part of the first and second
introns because of two reasons. One is that our hypothesis
is about exon and not intron methylation as nucleosome
positioning has shown to be more important in exons
[24]. Secondly the majority of the CpG’sa r ew i t h i nt h e
exon 2 (46/61) such that the first intron is 1520 bp long
and it contains 11 CpG within the last 264 bp and there
are 4 more CpGs within the beginning of the second
intron, whereas the whole of exon 2 is occupied with
CpGs. However our ongoing studies involve the examina-
tion of the intron methylation pattern as they also have
been implicated in gene expression regulation [25].
We observed a wide range of standard deviations from
both methylation and expression data (Figures 1 and 2).
This can be caused by the fact that we used total leukocyte
from FMF patients and healthy controls for analysis.
MEFV expression level shows differences between leuko-
cyte types such that there isn oM E F Ve x p r e s s i o ni n
lymphocytes. Additionally, we did not have the exact
information about different leukocyte levels which varies
from patient to patient, which lowers the resolution of the
data. Currently we are doing our analysis on subpopula-
tions of leukocytes i.e. monocytes and neutrophils.
MEFV gene has been shown to produce different tran-
scripts through alternative splicing [9-11]. In vitro studies
indicated that exon 2 deleted form (MEFV-d2)h a sa
nuclear localization in leukocytes and MEFV-d2: MEFV-fl
(full length) transcript ratio was about 3 fold higher in
mononuclear cells than in polymorphonuclear leukocytes
[9]. One way to test the role of exon 2 and its methylation
in expression in vitro is to do cell transfection studies with
alternative MEFV transcripts containing constructs. Full
length MEFV and two MEFV variants, exon 2 fully spliced
and exon 2 partially spliced (which only contain 9 CG
dinucleotides as opposed to 41 CG dinucleotides) forms
cloned into phCMV-CLUC vectors, along with methylated
forms were transfected into HeLa cells. According to our
preliminary results, the second exon fully spliced form of
MEFV was the highest in expression, and the full length
was the lowest in expression. Exon 2 partially spliced form
of MEFV was the middle compared to full length and
second exon fully spliced forms (data not shown) [26].
Furthermore we have also shown increased exon 2 spliced
form in FMF patients compared to controls (P = 0.026),
which may indicate a possible connection between methy-
lation and alternative splicing at this site [27]. These find-
ings are in accordance with our finding that the presence
of exon 2 and its methylation cause a decrease in gene
expression. Further in vitro and in vivo studies with differ-
ent leukocyte cell types are required to determine the
effect of exon 2 methylation in gene expression in correla-
tion with different alternatively spliced forms.
Conclusions
In summary, we confirmed the association between
reduced expression level of MEFV and FMF disease. Differ-
ent methylation levels of the gene between FMF patients
and healthy controls were observed, both groups having
mostly methylated exon 2, but methylation was higher in
FMF patients. To reveal the exact role of MEFV methyla-
tion in FMF and its relation to inflammation, we also aim
to increase the sample size and analyse FMF patients
during inflammatory attacks along with other auto-inflam-
matory and non-inflammatory disease control groups.
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